Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial — SHINE  

Diabetes Clinical Trial

Official title: Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

Status Completed

Clinical Trial Summary

The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial is a multicenter, randomized, controlled clinical trial of 1400 patients that will include approximately 60 enrolling sites. The study hypotheses are that treatment of hyperglycemic acute ischemic stroke patients with targeted glucose concentration (80mg/dL - 130 mg/dL) will be safe and result in improved 3 month outcome after stroke.

Clinical Trial Description

Eligible subjects must be randomized within 12 hours of stroke symptom onset and either have type 2 diabetes and glucose concentrations of over 110 mg/dL or no history of diabetes and glucose concentrations of 150 mg/dL or higher on initial evaluation. The enrolling sites include the Neurological Emergencies Treatment Trials (NETT) sites as well as non NETT sites from all over the United States. The study evaluates the safety and efficacy of targeted glucose control (treatment group - IV insulin with target 80-130 mg/dl) verses control therapy of sub q insulin plus basal insulin with target glucose less than 180 mg/ dL. ;

Related Conditions & MeSH terms

• Acute Ischemic Stroke
• Diabetes
• Hyperglycemia
• Stroke

• NCT number: NCT01369069
• Study type: Interventional
• Source: University of Virginia
• Status: Completed
• Phase: Phase 3
• Start date: April 2012
• Completion date: November 19, 2018